These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35316844)

  • 1. Treatment of Metastatic Melanoma in the Elderly.
    Seedor RS; Orloff M
    Curr Oncol Rep; 2022 Jul; 24(7):825-833. PubMed ID: 35316844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
    Rothermel LD; Zager JS
    Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virus preclinical toxicology studies.
    Rasa A; Alberts P
    J Appl Toxicol; 2023 May; 43(5):620-648. PubMed ID: 36299168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy.
    Knight AD; Luke JJ
    Curr Oncol Rep; 2024 Jul; 26(7):826-839. PubMed ID: 38789670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
    Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
    Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
    Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
    Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Oncolytic Viruses in the Treatment of Melanoma.
    Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
    Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy.
    Robert C
    Trends Mol Med; 2017 Nov; 23(11):983-985. PubMed ID: 29137714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of oncolytic virotherapy in the neoadjuvant setting.
    Thomas RJ; Bartee E
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35414592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
    Bommareddy PK; Patel A; Hossain S; Kaufman HL
    Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Viruses for the Treatment of Metastatic Melanoma.
    Trager MH; Geskin LJ; Saenger YM
    Curr Treat Options Oncol; 2020 Mar; 21(4):26. PubMed ID: 32266483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
    Corrigan PA; Beaulieu C; Patel RB; Lowe DK
    Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
    Ott PA; Hodi FS
    Clin Cancer Res; 2016 Jul; 22(13):3127-31. PubMed ID: 27146699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.